Mbx Biosciences Inc (MBX) Stock Price, Quote & News

Company Profile

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that i...

Industry: Biotechnology

Sector: Healthcare

Phone: 317 659 0200

Website: mbxbio.com

Address:

11711 North Meridian Street, Suite 300, Carmel, United States

laaarsas Aug. 2 at 9:53 AM

$MBX WHAT IS THIS RUN-UP!?!?

0 · Reply

Quantumup Jul. 29 at 12:43 PM

Mizuho⬆️ $MBX's PT to $91 from $57 and reiterated Outperform after updating its model. $LLY $VKTX NVO GPCR Mizuho updated its model to incorporate $10B in unadjusted peak U.S. sales for MBX-4291, a once-monthly candidate targeting the same GLP-1 mechanism as Eli Lilly's Zepbound—believes MBX-4291 can differentiate on competitive efficacy and a favorable tolerability profile.

0 · Reply

Quantumup Jul. 23 at 3:32 PM

UBS⬆️the price target on $MBX to $90 from $60, reiterated Buy and said that it remains bullish on the stock into the upcoming 12-week Ph I obesity readout in the 4Q—it continues to believe the stock is undervalued given the depth of MBX Biosciences' pipeline. $VKTX $GPCR NVO LLY

0 · Reply

DylanGFM Jul. 18 at 4:41 AM

$MBX bro they are good till 2029 and are really looking like they have been getting down to business there is so much they have going on $SPY this is the one that I wish I would of bought before when I put it in one of my watch lists after trading it and not holding long term. $MDLN

0 · Reply

DylanGFM Jul. 18 at 4:37 AM

$MBX How's everybody feeling about the transition?

0 · Reply

DylanGFM Jul. 18 at 4:26 AM

$MBX 'Phase 1: Generally well‑tolerated, no drug‑related severe/serious AEs reported.' At least it wouldn't sound like every damnone of those commercials where the list of side effects are as long as the whole damn RX ad itself. phase 3 initiation in Q3 and here say is very optimistic for the bull market regarding the rest of the year. It looks so perfect right now but don't forget to take profit when everyone else does I'm regretting not buying this a while back

0 · Reply

DylanGFM Jul. 18 at 4:07 AM

$MBX Son of a B. I had a feeling I was going to be regretting pulling long terms out of biotechs and only day trading them. This damn thing just kept going up haha

0 · Reply

OpenOutcrier Jul. 14 at 12:56 PM

$MBX (-6.1% pre) MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth https://ooc.bz/l/107704

0 · Reply

DonCorleone77 Jul. 14 at 1:08 AM

$MBX $QTTB $PENG $USEA $ERAS AFTER-HOURS MOVERS: Currently Higher: - Lulu's Fashion Lounge (LVLU) up 29.7% after announcing review of strategic alternatives - Vision Marine Technologies (VMAR) up 14.2% after Q3 pre-announcement - Trex Company (TREX) up 5.4% after above-consensus revenue pre-announcement - Weatherford (WFRD) up 1.1% on considered re-domestication from Ireland to Delaware Currently Lower After Earnings: - FB Financial (FBK) down 1.6% Currently Also Lower: - MBX Biosciences (MBX) down 6.5% after announcing leadership transition - Q32 Bio (QTTB) down 6.8% after announcing $200M common stock offering - Penguin Solutions (PENG) down 6.9% after announcing a convertible note offering - United Maritime (USEA) down 3.8% after equity offering - Erasca (ERAS) down 1.7% after equity offering.

0 · Reply

notreload_ai Jul. 13 at 8:55 PM

$MBX appoints Steve Hoerter as Chairman and CEO and John Smither as CFO. The moves are aimed at supporting the company’s next phase of growth in precision peptide therapies. https://notreload.xyz/xy/mbx-appoints-steve-hoerter-as-ceo-john-smither-as-cfo/

0 · Reply

MBX Biosciences price target raised to $91 from $57 at Mizuho

2026-07-23T13:41:21.000Z - 11 days ago

MBX Biosciences price target raised to $90 from $60 at UBS

2026-07-13T20:20:24.000Z - 21 days ago

MBX Biosciences CEO Kent Hawryluk steps down, Steve Hoerter succeeds

Jul 13, 2026, 4:15 PM EDT - 21 days ago

MBX Biosciences Announces Executive Leadership Transition to Support the Company's Next Phase of Growth

2026-06-12T12:20:09.000Z - 7 weeks ago

MBX Biosciences down 19% at $30.05 after announcing canvuparatide study results

Jun 12, 2026, 8:00 AM EDT - 7 weeks ago

MBX Biosciences Transcript: Study result

Jun 12, 2026, 8:00 AM EDT - 7 weeks ago

MBX Biosciences Slides: Study result

Jun 12, 2026, 8:00 AM EDT - 7 weeks ago

MBX Biosciences Press release: Study result

2026-06-12T11:10:08.000Z - 7 weeks ago

MBX Biosciences announces results from Avail, canvuparatide trials

Jun 12, 2026, 7:00 AM EDT - 7 weeks ago

MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

Jun 4, 2026, 8:00 AM EDT - 2 months ago

MBX Biosciences Transcript: AGM 2026

Jun 3, 2026, 8:10 AM EDT - 2 months ago

MBX Biosciences Transcript: Jefferies Global Healthcare Conference 2026

Jun 1, 2026, 8:00 AM EDT - 2 months ago

MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026

May 26, 2026, 8:00 AM EDT - 2 months ago

MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City

2026-05-12T16:23:49.000Z - 2 months ago

MBX Biosciences price target raised to $56 from $50 at Stifel

2026-05-12T10:07:50.000Z - 3 months ago

MBX Biosciences price target raised to $70 from $66 at Barclays

2026-05-12T09:47:56.000Z - 3 months ago

MBX Biosciences price target raised to $86 from $76 at Citizens

2026-05-11T19:43:52.000Z - 3 months ago

MBX Biosciences price target raised to $70 from $50 at Truist

May 11, 2026, 10:30 AM EDT - 3 months ago

MBX Biosciences Transcript: Status update

May 11, 2026, 10:30 AM EDT - 3 months ago

MBX Biosciences Press release: Status update

May 11, 2026, 10:30 AM EDT - 3 months ago

MBX Biosciences Slides: Status update

2026-05-11T13:40:04.000Z - 3 months ago

MBX Biosciences Phase 1 data supports once-monthly dosing for MBX 4291

May 11, 2026, 7:00 AM EDT - 3 months ago

MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing

May 8, 2026, 8:00 AM EDT - 3 months ago

MBX Biosciences Proxy statement: Proxy filing

2026-05-07T19:50:45.000Z - 3 months ago

MBX Biosciences reports Q1 EPS (51c), consensus (58c)

2026-05-07T18:59:32.000Z - 3 months ago

MBX Biosciences appoints Mark Soued as chief commercial officer.

ALNY

May 7, 2026, 8:00 AM EDT - 3 months ago

MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights

May 7, 2026, 7:00 AM EDT - 3 months ago

MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award

May 7, 2026, 7:00 AM EDT - 3 months ago

MBX Biosciences Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

MBX Biosciences Earnings release: Q1 2026

Apr 23, 2026, 8:00 AM EDT - 3 months ago

MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio

Apr 22, 2026, 8:00 AM EDT - 3 months ago

MBX Biosciences Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 3 months ago

MBX Biosciences Proxy statement: Proxy filing

Apr 3, 2026, 8:00 AM EDT - 4 months ago

MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2026-03-31T11:46:22.000Z - 4 months ago

MBX Biosciences initiated with an Outperform at LifeSci Capital

2026-03-12T20:10:19.000Z - 5 months ago

MBX Biosciences files automatic mixed securities shelf

2026-03-12T12:06:11.000Z - 5 months ago

MBX Biosciences reports Q4 EPS (49c), consensus (63c)

Mar 12, 2026, 8:00 AM EDT - 5 months ago

MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights

Mar 12, 2026, 7:00 AM EDT - 5 months ago

MBX Biosciences Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 5 months ago

MBX Biosciences Annual report: Q4 2025

Mar 11, 2026, 3:00 PM EDT - 5 months ago

MBX Biosciences Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 9:00 AM EDT - 5 months ago

MBX Biosciences Transcript: The Citizens Life Sciences Conference 2026

2026-03-10T12:22:36.000Z - 5 months ago

MBX Biosciences appoints Basbaum as Chief Business Officer

Mar 10, 2026, 8:00 AM EDT - 5 months ago

MBX Biosciences Appoints Karen Basbaum as Chief Business Officer

Mar 9, 2026, 10:21 AM EDT - 5 months ago

CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism

2026-03-09T12:13:30.000Z - 5 months ago

MBX Biosciences ‘on track’ to initiate Phase 3 in Q3 following EOP 2 meeting

Mar 9, 2026, 8:00 AM EDT - 5 months ago

MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism

Mar 2, 2026, 9:10 AM EST - 5 months ago

MBX Biosciences Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 11:20 AM EST - 5 months ago

MBX Biosciences Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 23, 2026, 8:00 AM EST - 5 months ago

MBX Biosciences to Participate in Upcoming March Investor Conferences

Feb 11, 2026, 8:00 AM EST - 6 months ago

MBX Biosciences to Participate in Upcoming Investor Conferences

2026-01-27T21:31:18.000Z - 6 months ago

MBX Biosciences initiated with an Overweight at Barclays

Jan 22, 2026, 8:00 AM EST - 6 months ago

MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair

Jan 13, 2026, 6:45 PM EST - 7 months ago

MBX Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 6:45 PM EST - 7 months ago

MBX Biosciences Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 4:00 PM EST - 7 months ago

MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference

Dec 15, 2025, 8:00 AM EST - 8 months ago

MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13

Dec 2, 2025, 4:00 PM EST - 8 months ago

MBX Biosciences Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 10:00 AM EST - 9 months ago

MBX Biosciences Transcript: TD Cowen Treatment Advancements in Obesity and Related Disorders Summit

Nov 19, 2025, 11:00 AM EST - 9 months ago

MBX Biosciences Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 8:00 AM EST - 9 months ago

MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference

Nov 12, 2025, 3:20 PM EST - 9 months ago

MBX Biosciences Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 3:30 PM EST - 9 months ago

MBX Biosciences Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 4:00 PM EST - 9 months ago

MBX Biosciences Earnings release: Q3 2025

Nov 6, 2025, 4:00 PM EST - 9 months ago

MBX Biosciences Quarterly report: Q3 2025

Nov 6, 2025, 8:00 AM EST - 9 months ago

MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Nov 6, 2025, 7:00 AM EST - 9 months ago

MBX Biosciences Registration statement: Registration Filing

Nov 5, 2025, 6:00 PM EST - 9 months ago

MBX Biosciences Slides: Corporate Presentation

Nov 3, 2025, 9:58 AM EST - 9 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MDGL MEDI

Oct 20, 2025, 8:00 AM EDT - 10 months ago

MBX Biosciences to Participate in November Investor Conferences

Sep 30, 2025, 10:00 AM EDT - 10 months ago

MBX Biosciences Transcript: Stifel Virtual Cardiometabolic Forum

Sep 29, 2025, 8:00 AM EDT - 11 months ago

MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum

Sep 24, 2025, 9:15 PM EDT - 11 months ago

MBX Biosciences Announces Pricing of Upsized Public Offering

Sep 22, 2025, 4:14 PM EDT - 11 months ago

MBX Biosciences Announces Proposed Public Offering

Sep 22, 2025, 8:00 AM EDT - 11 months ago

MBX Biosciences Transcript: Study Update

Sep 22, 2025, 8:00 AM EDT - 11 months ago

MBX Biosciences Press release: Study Update

Sep 22, 2025, 8:00 AM EDT - 11 months ago

MBX Biosciences Slides: Study Update

Sep 22, 2025, 8:00 AM EDT - 11 months ago

MBX Biosciences Registration statement: Registration Filing

Sep 22, 2025, 7:00 AM EDT - 11 months ago

MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension

Sep 19, 2025, 4:18 PM EDT - 11 months ago

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

Sep 4, 2025, 8:00 AM EDT - 11 months ago

MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity

Aug 7, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 7, 2025, 7:00 AM EDT - 1 year ago

MBX Biosciences Quarterly report: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 1 year ago

MBX Biosciences Earnings release: Q2 2025

Jun 23, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

Jun 16, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

Jun 10, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

Jun 9, 2025, 10:40 AM EDT - 1 year ago

MBX Biosciences Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 2:00 PM EDT - 1 year ago

MBX Biosciences Transcript: Jefferies Global Healthcare Conference 2025

May 21, 2025, 3:35 PM EDT - 1 year ago

MBX Biosciences Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences to Participate in June Investor Conferences

May 12, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 12, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences Quarterly report: Q1 2025

May 12, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences Earnings release: Q1 2025

May 7, 2025, 3:00 PM EDT - 1 year ago

MBX Biosciences Transcript: The Citizens JMP Life Sciences Conference 2025

Apr 23, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences Proxy statement: Proxy Filing

Apr 22, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences to Participate in Citizens and RBC May Investor Conferences

Apr 7, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 17, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Mar 17, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences Annual report: Q4 2024

Mar 17, 2025, 8:00 AM EDT - 1 year ago

MBX Biosciences Earnings release: Q4 2024

Mar 5, 2025, 8:00 AM EST - 1 year ago

MBX Biosciences Announces Additions to Leadership Team

Mar 3, 2025, 10:30 AM EST - 1 year ago

MBX Biosciences Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 8:00 AM EST - 1 year ago

MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism

Feb 18, 2025, 8:00 AM EST - 1 year ago

MBX Biosciences to Participate in March Investor Conferences

Feb 11, 2025, 8:40 AM EST - 1 year ago

MBX Biosciences Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 5, 2025, 2:00 PM EST - 1 year ago

MBX Biosciences Transcript: Guggenheim SMID Cap Biotech Conference

Jan 14, 2025, 5:15 PM EST - 1 year ago

MBX Biosciences Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 7, 2025, 8:30 AM EST - 1 year ago

MBX Biosciences Transcript: Study Result

Jan 7, 2025, 8:30 AM EST - 1 year ago

MBX Biosciences Press release: Study Result

Jan 7, 2025, 8:30 AM EST - 1 year ago

MBX Biosciences Slides: Study Result

Jan 7, 2025, 7:00 AM EST - 1 year ago

MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

Nov 20, 2024, 10:30 AM EST - 1 year ago

MBX Biosciences Transcript: Jefferies London Healthcare Conference 2024

Nov 18, 2024, 3:00 PM EST - 1 year ago

MBX Biosciences Transcript: Stifel 2024 Healthcare Conference

Nov 18, 2024, 8:00 AM EST - 1 year ago

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

Nov 12, 2024, 3:30 PM EST - 1 year ago

MBX Biosciences Transcript: Guggenheim Inaugural Global Healthcare Innovation Conference

Nov 7, 2024, 8:00 AM EST - 1 year ago

MBX Biosciences Quarterly report: Q3 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

MBX Biosciences Earnings release: Q3 2024

Oct 28, 2024, 8:00 AM EDT - 1 year ago

MBX Biosciences to Participate in Upcoming November Investor Conferences

Sep 30, 2024, 8:00 AM EDT - 2 years ago

MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

Sep 16, 2024, 4:05 PM EDT - 2 years ago

MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 13, 2024, 12:36 PM EDT - 2 years ago

MBX Biosciences shares surge 44% in blockbuster Nasdaq debut

Sep 12, 2024, 7:20 PM EDT - 2 years ago

MBX Biosciences raises $163.2 mln in US IPO

Sep 12, 2024, 7:11 PM EDT - 2 years ago

MBX Biosciences Announces Pricing of Initial Public Offering

laaarsas Aug. 2 at 9:53 AM

$MBX WHAT IS THIS RUN-UP!?!?

0 · Reply

Quantumup Jul. 29 at 12:43 PM

0 · Reply

Quantumup Jul. 23 at 3:32 PM

0 · Reply

DylanGFM Jul. 18 at 4:41 AM

0 · Reply

DylanGFM Jul. 18 at 4:37 AM

$MBX How's everybody feeling about the transition?

0 · Reply

DylanGFM Jul. 18 at 4:26 AM

0 · Reply

DylanGFM Jul. 18 at 4:07 AM

$MBX Son of a B. I had a feeling I was going to be regretting pulling long terms out of biotechs and only day trading them. This damn thing just kept going up haha

0 · Reply

OpenOutcrier Jul. 14 at 12:56 PM

$MBX (-6.1% pre) MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth https://ooc.bz/l/107704

0 · Reply

DonCorleone77 Jul. 14 at 1:08 AM

0 · Reply

notreload_ai Jul. 13 at 8:55 PM

0 · Reply

TheSealeGroup Jul. 8 at 4:50 PM

$MBX portfolio is dragging today. (Thank you war) But MBX does not know how to have a down day. Beautiful chart. Been in since $17. Will see if I can wait out for LT cap gains.

1 · Reply

AlaskaNoyes Jul. 8 at 3:49 PM

$MBX this stock never stays down, Green Days for ever

0 · Reply

TalkMarkets Jul. 7 at 9:22 PM

#Biotech Is The Next #AI Trade $XBI $MBX $STOK $XLF $SPY https://talkmarkets.com/article/biotech-is-the-next-ai-trade-1783459332

0 · Reply

arikpro Jul. 7 at 6:36 PM

$MBX why this shit cant go down ?!

0 · Reply

PolyhedronPivot Jul. 6 at 7:18 PM

$MBX MBX-4291 showing clean early readout. Week 8 looks on track for 8-9% weight loss in the first MAD cohort, with the blinded MAD data already pointing to ~7%. Safety also looks strong: no nausea or vomiting in the 15-60mg starting-dose group. Two mild cases only.

0 · Reply

arikpro Jul. 1 at 2:24 PM

$MBX bought puts here Enough is enough Sorry bears.

0 · Reply

QuietLattice Jun. 26 at 3:48 PM

$MBX 9:38 bar +2% on ~7x vol — and it actually moved together

0 · Reply

Quantumup Jun. 25 at 6:40 PM

Guggenheim⬆️ $AMLX-$40,⬆️GLP-1R antagonism penetration in severe PBH patients to 70%—market share to 90%—bull case = $55,⬆️to BEST IDEA and reiterated at Buy. $MBX Here's what Guggenheim said in its note to investors: https://x.com/Quantumup1/status/2070215249798774800?s=20

0 · Reply

Merlintrader Jun. 12 at 5:02 PM

$MBX Biotech Tape in Focus: $MBX Strengthens Phase 3 Setup, $JAZZ Hits Oncology Trial Risk, $KYMR Adds Platform Momentum https://www.merlintrader.com/biotech-tape-mbx-jazz-kymr/

0 · Reply

GetVector Jun. 12 at 12:55 PM

Vector Intelligence (VI) is an algorithm designed to predict potential outsized intraday moves. VI will select up to 4 stocks per day. Today's VI stocks: $MBX, $SHAZ.

0 · Reply

notreload_ai Jun. 12 at 12:47 PM

$MBX reported one-year canvuparatide data showing 57% of patients achieved the primary endpoint in chronic hypoparathyroidism. Despite consistent results and kidney/bone benefits, shares fell on durability concerns versus expectations and $ASND Yorvipath. https://notreload.xyz/xy/mbx-biosciences-canvuparatide-misses-market-expectations/

0 · Reply

Tokamak_ Jun. 12 at 12:27 PM

$MBX left the boat, look at yorvipath for comparison..

0 · Reply

Market Cap	3.14B
Revenue (ttm)	0.00
Net Income (ttm)	-86.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	390,700
Avg Vol	841,964
Day's Range	N/A - N/A
Shares Out	47.60M
Stochastic %K	59%
Beta	0.16
Analysts	Strong Sell
Price Target	$74.82